Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
// Ying Li 1 , Xuemin Zheng 2 , Min Gong 3, 4 , Jianning Zhang 1 1 Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China 2 Tianjin Institute of Pharmaceutical Research, Tianjin, China 3 School of Pharmacy, Tianjin Medical University, Tianjin, China 4 Department of Oncology, University of Oxford, Oxford, UK Correspondence to: Min Gong, email: kahongmg@163.com Jianning Zhang, email: liying11_@hotmail.com Keywords: blood brain barrier, low-density lipoprotein related protein-1, brain glioma, cell penetrating peptide, paclitaxel Received: August 08, 2016 Accepted: September 29, 2016 Published: October 17, 2016 ABSTRACT The challenge of effectively delivering therapeutic agents to the brain has created an entire field of active research devoted to overcoming the blood brain barrier (BBB) and efficiently delivering drugs to the brain. Angiopep-2 can trigger transcytosis and traverse the BBB by recognizing low-density lipoprotein related protein-1 (LRP-1) expressed on the brain capillary endothelial cells. Here, we designed a novel strategy for the delivery of drugs to the brain. The novel drug delivery system was a combination of a receptor-targeting ligand, such as low-density lipoprotein related protein 1, and a cell-penetrating peptide (CPP). It was hypothesized that this conjugate will enhance the delivery of associated therapeutic cargo across the BBB and increase the permeability of a solid tumor. Our findings indicate that the combination of these two agents in a delivery vehicle significantly improved translocation of small molecules (paclitaxel) into the brain compared to the vehicle treatment, which contained only receptor-targeting ligand. The application of this strategy could potentially expand the horizons for the treatment of central nervous system disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Demeule, M., Currie, J., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., Gabathuler, R., Castaigne, J., & Béliveau, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05492.x · Cited by 557 · cited 1×
“Receptor-mediated transcytosis (RMT) has been emerging as a successful strategy to conquer the BBB because brain capillary endothelial cells express many different receptors, including transferrin receptors, lowdensity lipoprotein-related protein 1 (LRP-1), and nicotine acetylcholine receptors [4, 5].”
BackgroundWilhelmus, M. M. M., Otte-Höller, I., van Triel, J. J. J., Veerhuis, R., Maat-Schieman, M. L. C., Bu, G., de Waal, R. M. W., & Verbeek, M. M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070050 · Cited by 138
Cited by
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
“Brain permeability enhancer Transiently open the BBB Mismatch between findings in rodents and humans [54-58],”
BackgroundThe blood–tumour barrier in cancer biology and therapy
Steeg, P. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00529-6 · Cited by 287
Tashima, T. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00854 · Cited by 120
Peptides as drug delivery vehicles across biological barriers
Ghosh, D., Peng, X., Leal, J., & Mohanty, R. P. (2018) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0374-0 · Cited by 102
Evolving new-age strategies to transport therapeutics across the blood-brain-barrier
Choudhari, M., Hejmady, S., Narayan Saha, R., Damle, S., Singhvi, G., Alexander, A., Kesharwani, P., & Kumar Dubey, S. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120351 · Cited by 74
Metadata
- Authors
- Li, Y., Zheng, X., Gong, M., & Zhang, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-10-17
- Volume
- 7
- Issue
- 48
- Pages
- 79401-79407
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2537916300
- Cited by
- 90
- References
- 2
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.